type here...

CATEGORIES

Patient Zone

LATEST

1...678...60Page 7 of 60

TRENDING

EDITORS CHOICE

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

Medika Life -
The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

Exclusive Medika Conversation with HIMSS Top Leadership – Inside Scoop on Key 2024 Priorities

Gil Bashe, Medika Life Editor -
HIMSS - World's top health IT society takes on pressing policy and patient care issues - AI, cybersecurity, info democratization and more are on the agenda!

Now Is the Time To Quit

Jennifer Mittler-Lee B.S. Pharma -
Smokers and former smokers are at increased risk of developing a more severe course of covid-19 infection, nearly double the rate of non-smokers.

mRNA Technology, Human DNA and The Traffic Flow of Genetic Material

Robert Turner, Founding Editor -
Can RNA from a SARS-Cov2 infection find its way into our DNA. A recent preprint suggests reasons why genetic viral material is showing up in PCR tests

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories